Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 90 clinical trials
Featured trial
HIV PREP: A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People ≥ 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection

The purpose of this study is to see if Lenacapavir is safe and effective to use as PrEP in Cisgender Men (CGM), Transgender Women (TGW), Transgender Men (TGM) and Gender Non-binary people (GNB), with a high risk of HIV infection. This study will also assess how effective LEN is when …

  • 0 views
  • 25 Aug, 2022
  • 1 location
An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens

The primary objectives of this study are to evaluate the efficacy of switching to a bictegravir (BIC) plus lenacapavir (LEN) regimen versus continuing on stable baseline regimen (SBR) in virologically suppressed people with human immunodeficiency virus (PWH) (Phase 2) and to evaluate the efficacy of switching to BIC/LEN fixed-dose combination …

  • 0 views
  • 20 Sep, 2022
  • 4 locations
Probiotic Supplementation for Those Immune Non-responders With HIV-1 Infection

Gut bacterial community diversity and composition, immune recovery and activation in peripheral plasma/mucosa, plasma levels of gut damage, microbial translocation and inflammation at baseline and after 6 months of receiving intervention will be analyzed.

  • 0 views
  • 25 Apr, 2022
  • 1 location
Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

To evaluate the safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus tenofovir disoproxil fumarate-based antiretroviral regimens in HIV-infected individuals with virological suppression.

  • 0 views
  • 12 Mar, 2022
  • 2 locations
A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)

EHVA T02 is an international, phase II, double-blind study to evaluate two experimental arms each compared to placebo control in HIV-1 positive participants to see if either has a clinically relevant impact on viral replication.

  • 0 views
  • 21 Jul, 2022
  • 2 locations
TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test various doses of the combination of the antibodies for safety and pharmacokinetics in suppressed subjects on cART. …

  • 0 views
  • 24 Jul, 2022
  • 2 locations
Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

The primary objective of this study is to evaluate safety and tolerability of dual anti-human immunodeficiency virus (HIV) envelope monoclonal antibodies (mAbs), VRC07-523LS and CAP256V2LS, in a sequential regimen with a toll-like receptor (TLR)7 agonist, vesatolimod (VES), when administered in virologically suppressed HIV-1 Clade C-infected women on antiretroviral therapy (ART) …

  • 0 views
  • 14 Jul, 2022
  • 1 location
Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b Adjuvanted With 3M-052-AF + Alum in Healthy, HIV-1 Uninfected Adult Participants

The clinical study is designed to evaluate the ability of two priming vaccine regimens to activate and induce the maturation of cross-reactive CD4 binding site (CD4-bs) antibodies, including VRC01-class antibodies. VRC01- class antibodies are highly desirable to elicit via vaccination because they have broad cover all clades of HIV and …

Accepts healthy volunteers
  • 0 views
  • 09 Aug, 2022
  • 1 location
Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age

To assess patient reported treatment satisfaction and medication tolerability in virologically suppressed HIV-1 infected adults who are at least 65 years of age who switch to a bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination regimen.

  • 0 views
  • 13 Dec, 2021
  • 1 location
A Phase 1, Open-label, Multicohort Study to Evaluate the Impact of Inhibitors and Inducers of Cytochrome P450 Enzyme (CYP)3A and/or P-glycoprotein (P-gp) on the Pharmacokinetics (PK) of Vesatolimod (VES) in Virologically Suppressed Adults With HIV-1 on Antiretroviral Therapy (ART)

The primary objectives of this study are to evaluate the impact of cobicistat (COBI) (P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and strong cytochrome P450 enzyme [CYP]3A inhibitor), voriconazole (VOR) (strong CYP3A inhibitor), and rifabutin (RFB) (moderate CYP3A inducer) on vesatolimod (VES) pharmacokinetics (PK) and to evaluate safety in virologically …

  • 0 views
  • 19 Sep, 2022
  • 2 locations